RedHill Unveils New Movantik Data For Opioid-Induced Constipation

RedHill Biopharma Ltd RDHL has announced new Movantik (naloxegol) Phase 3 study data analyses.
The three analyses included pooled data from two Phase 3 studies involving 891 treated patients across two doses (12.5 mg and 25 mg), compared to a total of 446 patients in the placebo arms.
It presented the data at the PAINWeek 2021.
New data demonstrated rapid onset of action and sustained and predictable improvement of key symptoms associated with opioid-induced constipation (OIC) in both a subgroup of patients aged above 65 years and across both low and high-dose opioid therapy.
In patients aged 65 years and above, Movantik achieved significantly better response rates vs. placebo, with rapid onset of action and a higher proportion of subjects achieving spontaneous bowel movement (SBM) and complete spontaneous bowel movement (CSBM) over the first 48 hours of treatment.
Additional data also shows that naloxegol delivers similar rapid and sustained symptom improvement for patients, irrespective of the opioid dose.
Related Content: Cantor Sees 'Compelling Investment Opportunity' In This Biopharma.
Price Action: RDHL shares closed 5.19% lower at $9.49 on Friday.